Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa in EBV-HLH With CNS Involvement
NCT05854225Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of thiotepa in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Primary endpoint: Clinical remission rate at 24 weeks. Status: unknown.
02
Drugs
thiotepa
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05854225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05854225.